The central histamine level in rat model of vascular dementia

Journal of Physiology and Pharmacology

Volumn 62, Issue 5, 2011, Pages 549-558

  Stasiak, A ^a   Mussur, M ^a   Unzeta, M ^b   Lazewska, D ^c   Kiec Kononowicz, K ^c   Fogel, W A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antagonist; Histamine; Histamine H3; Monoamine oxidase inhibition; Permanent bilateral occlusion of the common carotid arteries; Vascular dementia

Indexed keywords

1 [3 (4 TERTBUTYLOPHENOXY)PROPYL]PIPERIDINE; ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DL 76; HISTAMINE; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE METHYLTRANSFERASE; MONOAMINE OXIDASE B INHIBITOR; N (2 PROPYNYL) 2 (5 BENZYLOXY INDOLYL)METHYLAMINE; PF 9601N; TACRINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; HISTAMINE RELEASE; LATENT PERIOD; MALE; MOLECULAR PATHOLOGY; MULTIINFARCT DEMENTIA; NONHUMAN; PSYCHOMETRY; RAT; REFERENCE MEMORY; WORKING MEMORY;

ACETYLCHOLINESTERASE; ANIMALS; BRAIN; CAROTID STENOSIS; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; HISTAMINE; HISTAMINE H3 ANTAGONISTS; LEARNING; MALE; MEMORY; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RATS; RATS, WISTAR;

EID: 84855742323     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 2007; 113: 1-15.
2. Blandina P, Passani MB. Central histaminergic system interactions and cognition. EXS 2006; 98: 149-163.
3. Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 2011; 32: 242-249.
4. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71: 1-51.
5. Ishunina TA, Kamphorst W, Swaab DF. Metabolic alterations in the hypothalamus and basal forebrain in vascular dementia. J Neuropathol Exp Neurol 2004; 63: 1243-1254.
6. Passani MB, Lin JS, Hancock A, Crochet S, Blandina P. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004; 25: 618-625.
7. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7: 137-152.
8. Diaz NL, Waters CH. Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Expert Rev Neurother 2009; 9: 1781-1789.
9. Ronnemaa E, Zethelius B, Lannfelt L, Kilander L. Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord 2011; 31: 460-466.
10. Musial A, Bajda M, Malawska B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr Med Chem 2007; 14: 2654-2679.
11. Sanz E, Romera M, Bellik L, Marco JI, Unzeta M. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. Med Sci Monit 2004; 10: BR477- BR484.
12. Hermanowicz N. Drug therapy for Parkinson's disease. Semin Neurol 2007; 27: 97-105.
13. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004; 1: CD004395.
14. Perez V, Unzeta M. PF 9601N [N-(2-propynyl)-2-(5- benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice. Neurochem Int 2003; 42: 221-229.
15. Reynolds A, Laurie C, Mosley RL, Gendelman HE. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 2007; 82: 297-325.
16. Gallagher DA, Schapira AH. Etiopathogenesis and treatment of Parkinson's disease. Curr Top Med Chem 2009; 9: 860-868.
17. Facecchia K, Fochesato LA, Ray SD, Stohs SJ, Pandey S. Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. J Toxicol 2011; 2011: 683728.
18. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001; 15: 375-390.
19. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2: 539-547.
20. Massoulie J, Sussman J, Bon S, Silman I. Structure and functions of acetylcholinesterase and butyrylcholinesterase. Prog Brain Res 1993; 98: 139-146.
21. Chatonnet A, Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J 1989; 260: 625-634.
22. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909-918.
23. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006; 9: 101-124.
24. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994; 8: 744-751.
25. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
26. Alfirevic A, Mills T, Carr D, et al. Tacrine-induced liver damage: an analysis of 19 candidate genes. Pharmacogenet Genomics 2007; 17: 1091-1100.
27. Cumming P, Vincent SR. Inhibition of histamine-Nmethyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydroacridine (tacrine) and by beta-carbolines. Biochem Pharmacol 1992; 44: 989-992.
28. Morisset S, Traiffort E, Schwartz JC. Inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity. Eur J Pharmacol 1996; 315: R1-R2.
29. Rezak M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon 2007; 53: 214-222.
30. Cruces MA, Elorriaga C, Fernandez-Alvarez E. Acetylenic and allenic derivatives of 2-(5-benzyloxyindolyl) and 2-(5- hydroxyindolyl)methylamines: synthesis and in vitro evaluation as monoamine oxidase inhibitors. Eur J Med Chem 1991; 26: 33-41.
31. Cutillas B, Ambrosio S, Unzeta M. Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2- propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci Lett 2002; 329: 165-168.
32. Perez V, Unzeta M. PF 9601N [N-(2-propynyl)-2-(5- benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice. Neurochem Int 2003; 42: 221-229.
33. Petroianu G, Arafat K, Sasse BC, Stark H. Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. Pharmazie 2006; 61: 179-182.
34. Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008; 154: 1166-1181.
35. Lazewska D, Kiec-Kononowicz K. Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Pat 2010; 20: 1147-1169.
36. Perez V, Marco JL, Fernandez-Alvarez E, Unzeta M. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br J Pharmacol 1999; 127: 869-876.
37. Prat G, Perez V, Rubi A, Casas M, Unzeta M. The novel type B MAO inhibitor PF9601N enhances the duration of LDOPA- induced contralateral turning in 6-hydroxydopamine lesioned rats. J Neural Transm 2000; 107: 409-417.
38. Perez V, Moron J, Pasto M, Unzeta M. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N. Neurobiology (Bp) 2000; 8: 231-236.
39. Sanz E, Quintana A, Battaglia V, et al. Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5- benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells. J Neurochem 2008; 105: 2404-2417.
40. Sanz E, Quintana A, Valente T, Manso Y, Hidalgo J, Unzeta M. Monoamine oxidase-B activity is not involved in the neuroinflammatory response elicited by a focal freeze brain injury. J Neurosci Res 2009; 87: 784-794.
41. Arrang JM, Garbarg M, Schwartz JC. Autoinhibition of brain histamine release mediated by a novel class (H3) receptor of histamine. Nature 1983; 302: 832-837.
42. Schlicker E, Malinowska B, Kathmann M, Gothert M. Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol 1994; 8: 128-137.
43. Clapham J, Kilpatrick GJ. Histamine H3 receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes. Br J Pharmacol 1992; 107: 919-923.
44. Blandina P, Giorgetti M, Bartolini L, et al. Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 1996; 119: 1656-1664.
45. Ganellin CR, Leurquin F, Piripitsi A, et al. Synthesis of potent non-imidazole histamine H3-receptor antagonists. Arch Pharm (Weinheim) 1998; 331: 395-404.
46. Lazewska D, Kuder K, Ligneau X, et al. Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands. Bioorg Med Chem 2009; 17: 3037-3042.
47. Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 2008; 31: 2163-2181.
48. von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H. Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett 2009; 19: 538-542.
49. Apelt J, Ligneau X, Pertz HH, et al. Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. J Med Chem 2002; 45: 1128-1141.
50. Grassmann S, Apelt J, Sippl W, et al. Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities. Bioorg Med Chem 2003; 11: 2163-2174.
51. Samadi A, Chioua M, Bolea I, et al. Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem 2011; 46: 4665-4668.
52. Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem 2008; 15: 2433-2455.
53. Camps P, Formosa X, Galdeano C, Gomez T, et al. Tacrinebased dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. Chem Biol Interact 2010; 187: 411-415.
54. Yamada K, Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 2000; 88: 93-113.
55. Farkas E, Luiten PG, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev 2007; 54: 162-180.
56. Kumar A, Seghal N, Naidu PS, Padi SS, Goyal R. Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. Pharmacol Rep 2007; 59: 274-283.
57. Ni J, Ohta H, Matsumoto K, Watanabe H. Progressive cognitive impairment following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats. Brain Res 1994; 653: 231-236.
58. Otori T, Katsumata T, Muramatsu H, Kashiwagi F, Katayama Y, Terashi A. Long-term measurement of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin Exp Pharmacol Physiol 2003; 30: 266-272.
59. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998; 112: 1199-1208.
60. Taylor KM, Snyder SH. Isotopic microassay of histamine, histidine, histidine decarboxylase and histamine methyltransferase in brain tissue. J Neurochem 1972; 19: 1343-1358.
61. Fogel WA, Andrzejewski W, Maslinski C. Brain histamine in rats with hepatic encephalopathy. J Neurochem 1991; 56: 38-43.
62. Fowler CJ, Tipton KF. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J Neurochem 1982; 38: 733-736.
63. Bacciottini L, Passani MB, Mannaioni PF, Blandina P. Interactions between histaminergic and cholinergic systems in learning and memory. Behav Brain Res 2001; 124: 183-194.
64. Yalcin M, Savci V, Jochem J. Involvement of the cholinergic system in the central histamine-induced reversal of critical haemorrhagic hypotension in rats. J Physiol Pharmacol 2009; 60: 133-137.
65. Jochem J, Savci V, Filiz N, Rybus-Kalinowska B, Fogel WA, Yalcin M. Involvement of the histaminergic system in cytidine 5'-diphosphocholine-induced reversal of critical haemorrhagic hypotension in rats. J Physiol Pharmacol 2010; 61: 37-43.
66. de Almeida MA, Izquierdo I. Memory facilitation by histamine. Arch Int Pharmacodyn Ther 1986; 283: 193-198.
67. Motawaj M, Peoc'h K, Callebert J, Arrang JM. CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer's disease. J Alzheimers Dis 2010; 22: 861-871.
68. Philippu A, Prast H, Kraus MM. Histaminergic and cholinergic transmission in cognitive processes. In: Histamine Research in the New Millennium. T. Watanabe, H. Timmerma, K. Yanai, (eds). Elsevier Science B.V., 2001, pp. 33-38.
69. Prast H, Fischer HP, Prast M, Philippu A. In vivo modulation of histamine release by autoreceptors and muscarinic acetylcholine receptors in the rat anterior hypothalamus. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 599-604.
70. Arrang JM, Gulat-Marnay C, Defontaine N, Schwartz JC. Regulation of histamine release in rat hypothalamus and hippocampus by presynaptic galanin receptors. Peptides 1991; 12: 1113-1117.
71. Gulat-Marnay C, Lafitte A, Arrang JM, Schwartz JC. Regulation of histamine release and synthesis in the brain by muscarinic receptors. J Neurochem 1989; 52: 248-254.
72. Chen Z, Kamei C. Facilitating effects of histamine on spatial memory deficit induced by scopolamine in rats. Acta Pharmacol Sin 2000; 21: 814-818.
73. Motawaj M, Burban A, Davenas E, Arrang JM. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease. J Pharmacol Exp Ther 2011; 336: 479-487.
74. Prell GD, Green JP. Measurement of histamine metabolites in brain and cerebrospinal fluid provides insights into histaminergic activity. Agents Actions 1994; 41: C5-C8.
75. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 2007; 8: 621-632.
76. Ni JW, Matsumoto K, Li H-B, Murakami Y, Watanabe H. Neuronal damage and decrease of central acetylcholine level following permanent occlusion of bilateral common carotid arteries in rat. Brain Res 1995; 673: 290-296.
77. Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995; 28: 449-457.
78. Murakami Y, Tanaka E, Sakai Y, Matsumoto K, Li HB, Watanabe H. Tacrine improves working memory deficit caused by permanent occlusion of bilateral common carotid arteries in rats. Jpn J Pharmacol 1997; 75: 443-446.
79. Jackson JJ, Soliman MR. Effects of tacrine (THA) on spatial reference memory and cholinergic enzymes in specific rat brain regions. Life Sci 1996; 58: 47-54.
80. Liu J, Ho W, Lee NT, Carlier PR, Pang Y, Han Y. Bis(7)- tacrine, a novel acetylcholinesterase inhibitor, reverses AF64A-induced deficits in navigational memory in rats. Neurosci Lett 2000; 282: 165-168.
81. Lazewska D, Ligneau X, Schwartz JC, Schunack W, Stark H, Kiec-Kononowicz K. Ether derivatives of 3-piperidinopropan-1-ol as non-imidazole histamine H3 receptor antagonists. Bioorg Med Chem 2006; 14: 3522-3529.
82. Szafarz M, Szymura-Oleksiak J, Lazewska D, Kiec- Kononowicz K. LC-MS-MS Method for the analysis of new non-imidazole histamine H3 receptor antagonist 1-[3-(4- tert-butylphenoxy)propyl]piperidine in rat serumapplication to pharmacokinetic studies. Chromatographia 2011; 73: 913-919.
83. Battaglia V, Sanz E, Salvi M, Unzeta M, Toninello A. Protective effect of N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine (PF9601N) on mitochondrial permeability transition. Cell Mol Life Sci 2006; 63:1440-1448.
84. Bellik L, Dragoni S, Pessina F, Sanz E, Unzeta M, Valoti M. Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment of its ability to interact with reactive nitrogen species. Acta Biochim Pol 2010; 57: 235-239.